235 related articles for article (PubMed ID: 1951408)
1. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.
Paladino JA; Sperry HE; Backes JM; Gelber JA; Serrianne DJ; Cumbo TJ; Schentag JJ
Am J Med; 1991 Nov; 91(5):462-70. PubMed ID: 1951408
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics.
Grasela TH; Paladino JA; Schentag JJ; Huepenbecker D; Rybacki J; Purcell JB; Fiedler JB
DICP; 1991; 25(7-8):857-62. PubMed ID: 1949945
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections.
Peacock JE; Pegram PS; Weber SF; Leone PA
Am J Med; 1989 Nov; 87(5A):185S-190S. PubMed ID: 2686421
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.
Gallis HA; Brennan RO; Goodwin SD; Swinney V; Rumbaugh MM; Drew RH
Am J Med; 1989 Nov; 87(5A):176S-180S. PubMed ID: 2686418
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections.
Levine DP; McNeil P; Lerner SA
Am J Med; 1989 Nov; 87(5A):160S-163S. PubMed ID: 2686416
[TBL] [Abstract][Full Text] [Related]
6. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis.
Amodio-Groton M; Madu A; Madu CN; Briceland LL; Seligman M; McMaster P; Miller MH
Ann Pharmacother; 1996 Jun; 30(6):596-602. PubMed ID: 8792944
[TBL] [Abstract][Full Text] [Related]
7. Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.
Balfour JA; Faulds D
Pharmacoeconomics; 1993 May; 3(5):398-421. PubMed ID: 10146890
[TBL] [Abstract][Full Text] [Related]
8. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.
Fass RJ; Plouffe JF; Russell JA
Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361
[TBL] [Abstract][Full Text] [Related]
9. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
Modai J
Am J Med; 1989 Nov; 87(5A):243S-247S. PubMed ID: 2686426
[TBL] [Abstract][Full Text] [Related]
10. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
Lorian V; Pavletich K
Drugs Exp Clin Res; 1994; 20(5):209-14. PubMed ID: 7875058
[TBL] [Abstract][Full Text] [Related]
11. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study.
Villavicencio J; Asensio de Fernandez ME; Ramirez CA
Am J Med; 1989 Nov; 87(5A):191S-194S. PubMed ID: 2686422
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections.
Wacha H; Warren B; Bassaris H; Nikolaidis P;
Surg Infect (Larchmt); 2006 Aug; 7(4):341-54. PubMed ID: 16978077
[TBL] [Abstract][Full Text] [Related]
13. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.
Neu HC; Davidson S; Briones F
Am J Med; 1989 Nov; 87(5A):209S-212S. PubMed ID: 2511758
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.
Sifuentes-Osornio J; Macías A; Amieva RI; Ramos A; Ruiz-Palacios GM
Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin (intravenous/oral) versus ceftazidime in lower respiratory tract infections.
Haddow A; Greene S; Heinz G; Wantuck D
Am J Med; 1989 Nov; 87(5A):113S-115S. PubMed ID: 2686410
[TBL] [Abstract][Full Text] [Related]
16. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group.
Krumpe PE; Cohn S; Garreltes J; Ramirez J; Coulter H; Haverstock D; Echols R
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():117-28. PubMed ID: 10225582
[TBL] [Abstract][Full Text] [Related]
17. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
Davis C
Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
[TBL] [Abstract][Full Text] [Related]
18. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
[TBL] [Abstract][Full Text] [Related]
19. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial.
Gentry LO; Ramirez-Ronda CH; Rodriguez-Noriega E; Thadepalli H; del Rosal PL; Ramirez C
Arch Intern Med; 1989 Nov; 149(11):2579-83. PubMed ID: 2684078
[TBL] [Abstract][Full Text] [Related]
20. Use of intravenous ciprofloxacin in difficult-to-treat infections.
Giamarellou H; Galanakis N
Am J Med; 1987 Apr; 82(4A):346-51. PubMed ID: 3555059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
